Abstract
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that primarily binds and regulates oxidized low-density lipoprotein (LDL). Expression of LOX-1 is regulated by a feed-forward system stimulated by oxidized LDL (oxLDL), a major component of atherosclerosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. The ability of LOX-1 to bind many different ligands and control several atherogenic processes makes this receptor a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.
Keywords: Endothelium, lipids, reactive oxygen species, atherosclerosis, scavenger receptors, Class E, angiotensin II, hydroxymethylglutaryl- CoA reductase inhibitors, cytokines
Current Medicinal Chemistry
Title: Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Volume: 16 Issue: 21
Author(s): Allison B. Reiss, Kamran Anwar and Peter Wirkowski
Affiliation:
Keywords: Endothelium, lipids, reactive oxygen species, atherosclerosis, scavenger receptors, Class E, angiotensin II, hydroxymethylglutaryl- CoA reductase inhibitors, cytokines
Abstract: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that primarily binds and regulates oxidized low-density lipoprotein (LDL). Expression of LOX-1 is regulated by a feed-forward system stimulated by oxidized LDL (oxLDL), a major component of atherosclerosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. The ability of LOX-1 to bind many different ligands and control several atherogenic processes makes this receptor a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.
Export Options
About this article
Cite this article as:
Reiss B. Allison, Anwar Kamran and Wirkowski Peter, Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review, Current Medicinal Chemistry 2009; 16 (21) . https://dx.doi.org/10.2174/092986709788681994
DOI https://dx.doi.org/10.2174/092986709788681994 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Markers of Early Vascular Ageing
Current Pharmaceutical Design Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice
Current Pharmaceutical Biotechnology Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Platelet Function in Inflammatory Diseases: Insights from Clinical Studies
Inflammation & Allergy - Drug Targets (Discontinued) Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Applications of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Pulmonary Disease
Current Respiratory Medicine Reviews Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Current Medicinal Chemistry The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews